By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
The most likely explanation is that the rate of events in the BIS were less than the DEN group.
Bisphosphonates MACE risk reduction are demonstrated in different trials. It's likely one of the explanations for the romosozumab "risk signal" which was absent in the placebo controlled trial but emerged when compared with alendronate.